RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 92.6%

Neg 0% Neu 0% Pos 92.6%

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.